AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11022177
Drug: Subcutaneous octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous octreotide (mean exposure of 3 years); n=231
Trial: 11022177
Drug: Intramuscular Sandostatin
RxNorm normalized name: Sandostatin
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular Sandostatin LAR (mean exposure of 2.5 years); n=47
Trial: 18836324
Drug: Silver sulfadiazine
RxNorm normalized name: Silver Sulfadiazine
DrugBank: Silver sulfadiazine (DB05245)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver sulfadiazine cream (SSC)
Trial: 10225478
Drug: ACE-Inhibitors
RxNorm normalized name: Gastric inhibitory polypeptide
DrugBank: Gastric inhibitory polypeptide (DB15217)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE-Inhibitors
Trial: 10225478
Drug: no pharmacological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no pharmacological treatment
Trial: 8550304
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) injections of narcotics
Trial: 95728
Drug: Minoxidil in
RxNorm normalized name: Product containing minoxidil in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minoxidil in combination with propranolol and diuretics
Trial: 95728
Drug: Other drugs
RxNorm normalized name: Other drugs for bile therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other drugs (comparable group)
Trial: 28617838
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg tesamorelin
Trial: 23975476
Drug: Fluoxetine (directly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (directly observed treatment)
Trial: 16815689
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of piperacillin (2 g i.v. over 0.5 h as a loading dose followed by 8 g i.v. daily over 24 h)
Trial: 16815689
Drug: Intermittent infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent infusion of piperacillin (3 g i.v. every 6h over 0.5 h)
Trial: 16815689
Drug: Intermittent infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent infusion of piperacillin
Trial: 15049402
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg tablet once daily for 2 weeks
Trial: 9491825
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II infusion (FBF ratios)
Trial: 9491825
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II infusion (FBF)
Trial: 9491825
Drug: Noradrenaline infusion
RxNorm normalized name: noradrenaline hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noradrenaline infusion (FBF ratios)
Trial: 9491825
Drug: Noradrenaline infusion
RxNorm normalized name: noradrenaline hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noradrenaline infusion (FBF)
Trial: 7828793
Drug: Isradipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (5 mg b.i.d.)
Trial: 3144615
Drug: Short-term MF
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term MF chemotherapy (mitomycin C 0.04 mg/kg plus 5-fluorouracil 5.0 mg/kg x 6 bolus i.v.)
Trial: 3144615
Drug: MF plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF plus long-term HCFU chemotherapy (HCFU 6-12 mg/kg/day over 12 weeks, p.o.)
Trial: 30113526
Drug: Canagliflozin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin (300 mg daily)
Trial: 23385285
Drug: Paclitaxel (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (80 mg/m), Carboplatin (6 times AUC), Vorinostat (200 mg) every 28 days for 6 cycles
Trial: 23385285
Drug: Paclitaxel (135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (135 mg/m) and Vorinostat (400 mg) maintenance chemotherapy every 28 days for 12 cycles
Trial: 23385285
Drug: Primary induction
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary induction chemotherapy
Trial: 20951505
Drug: TARGeted Intraoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TARGeted Intraoperative radioTherapy (Targit) boost with a single dose of 20 Gy
Trial: 17236593
Drug: rhGH 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH 0.15 U/kg daily from day 3 to day 9 after operation
Trial: 12895016
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy based on a two‐stage model of trauma treatment including Dialectical Behavior Therapy skills and writing assignments
Trial: 9751910
Drug: 75 microg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 microg/kg each of morphine and midazolam
Trial: 9751910
Drug: 75 microg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 microg/kg morphine and 50 microg/kg midazolam
Trial: 9751910
Drug: 50 microg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg/kg morphine and 75 microg/kg midazolam
Trial: 9751910
Drug: 50 microg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg/kg each of morphine and midazolam
Trial: 3940501
Drug: Cimetidine (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1200 mg/d) + Metoclopramide (40 mg/d)
Trial: 3940501
Drug: Cimetidine (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1200 mg/d) + Placebo
Trial: 26984513
Drug: Physical exercise
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical exercise (PE) program, 0.5-1 hour duration at least twice weekly for at least 3 months, with continuation encouraged thereafter.
Trial: 22951014
Drug: Celecoxib 400mg
RxNorm normalized name: CELECOXIB 400MG CAP
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 400mg b.i.d. in combination with two-drug platinum-based chemotherapy
Trial: 22951014
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combination with two-drug platinum-based chemotherapy
Trial: 19960257
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with amantadine (200 mg daily)
Trial: 19960257
Drug: Double therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double therapy (peginterferon alpha-2a plus weight-based ribavirin for 48 weeks)
Trial: 18256841
Drug: Anti-VEGF treatment
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-VEGF treatment via intravitreal administration
Trial: 12465698
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose (DD) of normal-release morphine at bedtime
Trial: 12465698
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose (SD) of normal-release morphine at bedtime
Trial: 10709388
Drug: Ketorolac, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac, 60 mg i.v.
Trial: 10709388
Drug: Propacetamol, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propacetamol, 2 g i.v.
Trial: 10709388
Drug: Tramadol, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol, 200 mg i.v.
Trial: 7491837
Drug: Transdermal ERT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal ERT (50 micrograms 17‐beta‐estradiol/24 hours)
Trial: 7491837
Drug: Oral ERT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ERT (0.6 mg conjugated estrogens + 5 mg medrogestone on days 11-21 for three cycles)
Trial: 2109336
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone (GnRH) analog
Trial: 28031424
Drug: Dalantercept 0.6,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalantercept 0.6, 0.9, or 1.2 mg/kg subcutaneously every 3 weeks plus axitinib 5 mg by mouth twice daily
Trial: 26020821
Drug: Rebamipide ophthalmic
RxNorm normalized name: Rebamipide
DrugBank: Rebamipide (DB11656)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Rebamipide ophthalmic suspension
Trial: 19683731
Drug: Transdermal oxybutynin
RxNorm normalized name: oxybutynin Transdermal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal oxybutynin (1.3, 2.9 or 3.9 mg daily)
Trial: 19683731
Drug: Oral oxybutynin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oxybutynin (5, 10 or 15 mg daily)
Trial: 11045862
Drug: Dexfenfluramine 7.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexfenfluramine 7.5, 15, 22.5, and 30 mg bid
Trial: 8960715
Drug: Gabapentin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (800 mg, t.i.d.)
Trial: 1552095
Drug: Quinidine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine and Verapamil (1,500 mg + 240 mg/day)
Trial: 3888731
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily treatment with 1% tioconazole cream
Trial: 3888731
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily treatment with 1% tioconazole cream
Trial: 29746891
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract (500 mg/day)
Trial: 26702991
Drug: Dutasteride 0.5
RxNorm normalized name: dutasteride 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride 0.5 mg, Bicalutamide 50 mg daily, and Tamoxifen 10 mg daily for 3 months (D + B group)
Trial: 26702991
Drug: LHRH agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH agonists and Bicalutamide daily for 1 month (LHRH group)
Trial: 1888238
Drug: Marine oil
RxNorm normalized name: marine non-gelling gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marine oil capsules (4.5 g of omega-3 fatty acids, or nine to 18 capsules daily)
Trial: 1888238
Drug: Marine oil
RxNorm normalized name: marine non-gelling gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marine oil capsules
Trial: 31892609
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of vitamin D3
Trial: 12860772
Drug: 20 mg/d
RxNorm normalized name: Valtoco, 20 mg/dose nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/d aripiprazole
Trial: 12860772
Drug: 30 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/d aripiprazole
Trial: 12860772
Drug: 6 mg/d
RxNorm normalized name: EMSAM 6 MG/Day 24HR Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/d risperidone
Trial: 12860772
Drug: 20 mg/d
RxNorm normalized name: Valtoco, 20 mg/dose nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/d aripiprazole and 6 mg/d risperidone
Trial: 6614419
Drug: Flunitrazepam 1.5-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam 1.5-2 mg p.o. the evening before operation (Group 1)
Trial: 6614419
Drug: Flunitrazepam 1.5-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam 1.5-2 mg p.o. the evening before and the morning of operation (Group 2)
Trial: 6614419
Drug: Lormetazepam 2-2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lormetazepam 2-2.5 mg p.o. the same time as Group 2 (Group 3)
Trial: 6614419
Drug: Nitrazepam 5
RxNorm normalized name: nitrazepam 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrazepam 5 mg p.o. the evening before operation and pethidine 50-100 mg combined with promethazine 25 mg i.m. 60 min before surgery (Group 4)
Trial: 26603558
Drug: Early intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early intravitreal betamethasone injection (early-IVB)
Trial: 26603558
Drug: Delayed intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed intravitreal betamethasone injection (delayed-IVB)
Trial: 23529990
Drug: Laxative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laxative treatment prior to endoscopic biopsy
Trial: 15741420
Drug: Homeopathic preparation
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic preparation of common allergens
Trial: 9671428
Drug: Fenoldopam (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoldopam (all doses)
Trial: 8747563
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) mivacurium 0.15 mg/kg with stable general anesthesia
Trial: 8747563
Drug: Single bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bolus administration of mivacurium
Trial: 2468447
Drug: 10% low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% low MW hydroxyethyl starch (pentastarch) infusion
Trial: 31299400
Drug: Complex polypharmacy
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex polypharmacy (use of ≥3 BD medications)
Trial: 25481791
Drug: Olaparib plus
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib plus chemotherapy (paclitaxel and carboplatin)
Trial: 25481791
Drug: Olaparib plus
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib plus chemotherapy
Trial: 21887905
Drug: Sublingual piroxicam
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual piroxicam 40 mg
Trial: 15570646
Drug: Colchicine 0.6
RxNorm normalized name: colchicine 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.6 mg po bid
Trial: 11529362
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide (Kenacort A) injection on the left side after tonsillectomy and uvulopalatopharyngoplasty
Trial: 1151895
Drug: Two task-related
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two task-related warm-up treatments
Trial: 26405668
Drug: Intranasal corticosteroid
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal corticosteroid spray (ICS) 200 µg bid
Trial: 26405668
Drug: Open-label nebulized
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label nebulized saline solution (NS)
Trial: 26405668
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (NHA, ICS, ICS + NHA)
Trial: 21478142
Drug: Calcium dobesilate
RxNorm normalized name: CALCIUM DOBESILATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium dobesilate (CaD) 3 × 500 mg/day
Trial: 17052581
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of alfentanil
Trial: 10381854
Drug: Resting energy
RxNorm normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Resting energy expenditure-fat diet + simvastatin 10mg daily
Trial: 10381854
Drug: National Cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: National Cholesterol Education Program step 2 diet + simvastatin 10mg daily
Trial: 8689858
Drug: Acarbose, 100
RxNorm normalized name: Acarbose, 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose, 100 mg t.d.s. for 16 weeks
Trial: 31694495
Drug: Aprepitant oral
RxNorm normalized name: aprepitant Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant oral suspension (125 mg)
Trial: 31694495
Drug: Aprepitant capsule
RxNorm normalized name: Aprepitant Capsules
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant capsule (125 mg)
Trial: 28412650
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg plus evacetrapib 130 mg
Trial: 28412650
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg plus placebo
Trial: 23075177
Drug: Linezolid therapy
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linezolid therapy starting immediately at a dose of 600 mg per day
Trial: 23075177
Drug: Linezolid therapy
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linezolid therapy starting after 2 months at a dose of 600 mg per day
Trial: 23075177
Drug: Linezolid therapy
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linezolid therapy at a dose of 300 mg per day after second randomization
Trial: 23075177
Drug: Linezolid therapy
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linezolid therapy at a dose of 600 mg per day after second randomization
Trial: 23075177
Drug: Linezolid therapy
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linezolid therapy (both dosages)
Trial: 25234807
Drug: Linezolid therapy
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linezolid therapy
Trial: 17019624
Drug: Risperidone (1.37
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (1.37 mg/day)
Trial: 11913107
Drug: Routine radioiodide
RxNorm normalized name: Radioiodine
DrugBank: Iodide I-131 (DB09293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine radioiodide ablative therapy
Trial: 7576677
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) clonidine (loading dose of 4 micrograms/kg in 20 minutes at anesthesia induction, followed by a continuous infusion of 2 micrograms/kg/h until the end of surgery)
Trial: 2895564
Drug: Isosorbide-5-mononitrate (5-ISMN)
RxNorm normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide-5-mononitrate (5-ISMN) 60 mg, Imdur, once daily
Trial: 28385919
Drug: Higher protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher protein (HIGH: 1,103 kcal/day, 133 g protein/day)
Trial: 28385919
Drug: Moderate protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate protein (MOD: 974 kcal/day, 84 g protein/day)
Trial: 28385919
Drug: Carbohydrate‐based low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate‐based low protein control (CON: 1,042 kcal/day, 7 g protein/day)
Trial: 23718024
Drug: Botulotoxin preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulotoxin preparation (Disport) injected between internal and external anal sphincter portions, 90 units, 5-15 days preoperatively.
Trial: 23718024
Drug: No botulotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No botulotoxin injection (control group).
Trial: 18667054
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg 5-Loxin daily for 90 days
Trial: 18667054
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg 5-Loxin daily for 90 days
Trial: 21190858
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A injections combined with comprehensive rehabilitation
Trial: 12039463
Drug: Crinone 8%
RxNorm normalized name: Crinone 8% Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crinone 8% (n = 73) vaginally once daily
Trial: 12039463
Drug: Utrogest (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Utrogest (n = 53) vaginally three times daily (600 mg)
Trial: 10756833
Drug: Implant application
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant application
Trial: 10756833
Drug: Follow-up cooperation
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up cooperation regarding oral hygiene
Trial: 11174772
Drug: Preoperative antiplatelet
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative antiplatelet agents
Trial: 11174772
Drug: Intraoperative heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative heparin
Trial: 27096858
Drug: Oral carbohydrate
RxNorm normalized name: omega-3 carboxylic acids Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral carbohydrate supplement (12.5% carbohydrate, 400ml six hours and 200ml two hours before surgery)